Developmental stage modulates the prognostic impact of RAS pathway mutations in AML patients undergoing Allo-HSCT.

ABSTRACT: The RAS pathway and developmental stage are known to influence leukemic cell proliferation and drug resistance. However, their impact on the prognosis of acute myeloid leukemia (AML) patients, particularly post-allo-HSCT, remains unclear. This study aimed to explore the effects of RAS-pathway mutations and developmental stage on the outcomes of AML patients who received allo-HSCT. A total of 364 consecutive adult AML patients who underwent their first allo-HSCT with myeloablative conditioning were enrolled in this study. The primary endpoint of this study was the cumulative incidence of relapse (CIR) and secondary endpoints were OS and leukemia-free survival (LFS). RAS-pathway mutations were detected in 57 patients (15.7%). Subgroup analysis revealed opposite outcomes: RAS-pathway mutation

SUBMITTER: Yuan X 

PROVIDER: S-EPMC12619776 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature